Lupin is currently trading at Rs. 2060.85, up by 19.90 points or 0.98% from its previous closing of Rs. 2040.95 on the BSE.
The scrip opened at Rs. 2044.80 and has touched a high and low of Rs. 2113.00 and Rs. 2044.80 respectively. So far 54004 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1493.75 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 2113.00 and Rs. 1973.95 respectively. The current market cap of the company is Rs. 93946.57 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 46.88% and 6.20% respectively.
Following the recent approval received from the United States Food and Drug Administration (USFDA), Lupin has launched Tolvaptan Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg in the United States (US). The company holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity.
Tolvaptan Tablets are bioequivalent to Jynarque Tablets, 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, of Otsuka Pharmaceutical Company, and are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan Tablets (RLD Jynarque) had an estimated annual sale of $1,467 million in the US (fiscal year ended December 31, 2024).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: